Document Detail

Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series.
MedLine Citation:
PMID:  21283157     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To report the results of pediatric choroidal neovascular membranes (CNVMs) secondary to a variety of etiologies treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
DESIGN: Retrospective case series.
PARTICIPANTS: Four pediatric patients at the Hosptial for Sick Children with CNVMs secondary to a variety of etiologies.
METHODS: Each patient received multiple treatments with one of the following anti-VEGF agents: pegaptanib sodium, bevacizumab, or ranibizumab. Progress was monitored by clinical exam, optical coherence tomography (OCT), and fluorescein angiography.
RESULTS: The mean age of our patients was 11.5 years (range, 8-15 years). Patients were followed for a mean of 10 months (range, 4-14 months). One patient was treated with pegaptanib sodium, 2 with bevacizumab, and 1 with ranibizumab. Following treatment, 1 patient showed an improvement and 3 showed stabilization of vision with reduction of fluid on clinical exam and OCT, and cessation of leakage on the fluorescein angiogram. Patients required 2-5 injections of the anti-VEGF agent. No ocular or systemic adverse events were observed in any of our treated patients.
CONCLUSIONS: Anti-VEGF agents were effective in the treatment of pediatric CNVMs in this case series. However, we do not know how these results would have differed from other treatment modalities, including observation. We did not observe any adverse side effects; however, larger studies are required to document the safety of these medications in the pediatric population where normal angiogenesis is occurring.
Radha P Kohly; Rajeev H Muni; Peter J Kertes; Wai-Ching Lam
Related Documents :
3981957 - Local hirudin application--an aid in preventing occlusion of an arteriovenous fistula i...
9205167 - Bidirectional cavopulmonary shunt in patients with anomalies of systemic and pulmonary ...
17047967 - Is there an indication for etv in young infants in aetiologies other than isolated aque...
12398967 - Measurement of coronary flow reserve in the anterior and posterior descending coronary ...
12081777 - Distal hypospadias: which repair?
15624737 - The use of a novel intense pulsed light and heat source and ala-pdt in the treatment of...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Canadian journal of ophthalmology. Journal canadien d'ophtalmologie     Volume:  46     ISSN:  0008-4182     ISO Abbreviation:  Can. J. Ophthalmol.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-01     Completed Date:  2011-03-23     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0045312     Medline TA:  Can J Ophthalmol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  46-50     Citation Subset:  IM    
Department of Ophthalmology & Vision Sciences, University ofToronto, Toronto, Ont.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Aptamers, Nucleotide / therapeutic use
Choroidal Neovascularization / diagnosis,  drug therapy*,  etiology
Fluorescein Angiography
Intravitreal Injections
Retrospective Studies
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Visual Acuity
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Aptamers, Nucleotide; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/pegaptanib; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients...
Next Document:  High-density silicone oil as an intraocular tamponade in complex retinal detachments.